AURIEL-PsO: A randomised, double-blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB110222 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
CONCLUSIONS: Therapeutic equivalence between MSB11022 and reference adalimumab was demonstrated. AURIEL-PsO provides evidence to support the similarity of both products with regard to efficacy, safety and immunogenicity. This article is protected by copyright. All rights reserved.
PMID: 31206593 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ Tags: Br J Dermatol Source Type: research